secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K/A
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0000950170-24-061079
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics grants 25,000 stock options to Interim CFO Bryant D. Lim
-----------------------------------------------------------------------------

- Options to purchase 25,000 shares of common stock at $3.86 per share.
- Options vest over 4 years (25% at 1 year, then monthly); 10-year term.
- Grant approved by Compensation Committee on May 14, 2024, under 2020 Equity Incentive Plan.
- Amendment to prior 8-K reporting Lim's appointment as Interim CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024061079/0000950170-24-061079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024061079/prld-20240408.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-061079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer